-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Colorectal cancer (CRC) is a common malignant tumor in China and the world
Colorectal cancer (CRC) is a common malignant tumor in China and the world
The study included 69 patients with CRC who received ICB treatment at Sun Yat-sen University Cancer Hospital from March 1, 2017 to October 1, 2019
The study included 69 patients with CRC who received ICB treatment at Sun Yat-sen University Cancer Hospital from March 1, 2017 to October 1, 2019
The median age at the beginning of ICB treatment was 45 years (range 16-67 years)
Before immunotherapy, 55 cases (79.
The median time from the initial diagnosis of CRC to the first ICB treatment was 6.
As of January 4, 2021, all patients had a median follow-up of 15.
Univariate analysis found that dMMR/MSI-H status and the use of early immunotherapy were significantly associated with good OS (P<0.
65 patients reported treatment-related adverse events (TRAE)
In summary, like clinical studies, ICB is more effective for dMMR/MSI-H compared to pMMR/MSI-L/MSS CRC patients
Original source:
Zhou C, Jiang T, Li R, et al.
Zhou C, Jiang T, Li R, et al.
Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real-world retrospective analysis.
Cancer Commun (Lond).
2021 Jul 30.
doi: 10.
1002/cac2.
12199.
Epub ahead of print.
PMID: 34327863.
Leave a message here